Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence

被引：0
|
作者：
Inês Soares de Pinho
Paulo Luz
Lucy Alves
Raquel Lopes-Brás
Vanessa Patel
Miguel Esperança-Martins
Lisa Gonçalves
Ritas Freitas
Diana Simão
Maria Roldán Galnares
Isabel Fernandes
Silvia Artacho Criado
Salvador Gamez Casado
Jose Baena Cañada
Isabel M. Saffie Vega
João G. Costa
Ana S. Fernandes
Rita Teixeira de Sousa
Luís Costa
机构：
[1] Hospital de Santa Maria,Medical Oncology Department
[2] CHULN,Medical Oncology Department
[3] Centro Hospitalar Universitário do Algarve,Department of Biomedical Sciences
[4] CBIOS-Universidade Lusófona’s Research Center for Biosciences and Health Technologies,Medical Oncology Department
[5] University of Alcalá,Medical Oncology Department
[6] Hospital Prof. Dr. Fernando Fonseca,Pharmacy Department
[7] Centro Hospitalar Lisboa Central,Medical Oncology Department
[8] Hospital Virgen de Valme,Medical Oncology Department
[9] Centro Hospitalar Barreiro-Montijo,undefined
[10] Hospital Universitário Puerta del Mar,undefined
[11] Unidad de Cirugía Oncológica y Reconstructiva Mamaria,undefined
来源：
Clinical Drug Investigation | 2023年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 698
页数：7
相关论文
共 50 条
  • [1] Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+Breast Cancer: Real-World Evidence
    de Pinho, Ines Soares
    Luz, Paulo
    Alves, Lucy
    Lopes-Bras, Raquel
    Patel, Vanessa
    Esperanca-Martins, Miguel
    Goncalves, Lisa
    Freitas, Ritas
    Simao, Diana
    Galnares, Maria Roldan
    Fernandes, Isabel
    Criado, Silvia Artacho
    Casado, Salvador Gamez
    Canada, Jose Baena
    Vega, Isabel M. Saffie
    Costa, Joao G.
    Fernandes, Ana S.
    de Sousa, Rita Teixeira
    Costa, Luis
    [J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 691 - 698
  • [2] The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data
    Andreia Borges
    Filipa Pereira
    Patrícia Redondo
    Luís Antunes
    Cláudia Vieira
    Pedro Antunes
    Maria José Bento
    Susana Sousa
    José Machado Lopes
    Francisco Rocha-Gonçalves
    Joaquim Abreu de Sousa
    Deolinda Sousa Pereira
    Marina Borges
    [J]. Health Economics Review, 11
  • [3] Neoadjuvant trastuzumab and pertuzumab in combination with anthracyclines in HER2-positive early breast cancer: real-world data on effect of body mass index in cardiac safety
    Simao, Diana
    Sardinha, Mariana
    Gil, Lucia
    Montenegro, Alexandra
    Mendes, Jose
    Fernandes, Leonor
    Winckler, Patricia
    Luz, Ricardo
    Oliveira, Sonia
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [4] Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama
    Rodriguez, Franklin Castillero
    Castillo-Fernandez, Omar
    Lim-Law, Maria
    Palacios, Cristiane Martin
    Montano, Lilian
    Benitez, Stephanie
    Samudio, Jaime
    [J]. BREAST CANCER MANAGEMENT, 2021, 10 (01)
  • [5] Real-world treatment in patients with HER2+ metastatic breast cancerTreatment decisions in HER2+ mBC
    R. Colomer
    P. Hall
    M. Szkultecka-Debek
    R. C. Bondi
    A. Flinois
    S. Auziere
    J. Y. Le Cléac’h
    [J]. Breast Cancer Research and Treatment, 2018, 168 : 197 - 205
  • [6] Are anthracyclines needed for the neoadjuvant treatment of patients with HER2-positive early breast cancer?
    Jagiello-Gruszfeld, Agnieszka Irena
    Pogoda, Katarzyna
    Niwinska, Anna
    Lemanska, Izabela
    Szombara, Ewa
    Gorniak, Anna
    Jagielska, Beata
    Nowecki, Zbigniew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Anthracycline versus no anthracycline neoadjuvant therapy for HER2 breast cancer: real world evidence
    De Pinho, I. Soares
    Simao, D.
    Roldan Galanares, M.
    Lopes-Bras, R.
    Patel, V.
    Esperanca-Martins, M.
    Goncalves, L.
    Alves, L.
    Fernandes, I.
    Gamez Casado, S.
    Artacho Criado, S.
    Baena Canada, J.
    Costa, J.
    Fernandes, A. S.
    de Sousa, R. Teixeira
    Costa, L.
    Luz, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 175 : S62 - S62
  • [8] Anthracyclines in the treatment of HER2-negative breast cancer
    Paik, Soonmyung
    Taniyama, Yusuke
    Geyer, Charles E., Jr.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01) : 2 - 4
  • [9] Liposomal anthracyclines: Adjuvant and neoadjuvant therapy for breast cancer
    Campos, S
    [J]. ONCOLOGIST, 2003, 8 : 10 - 16
  • [10] Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer
    Montemurro, Filippo
    Rossi, Valentina
    Nole, Franco
    Redana, Stefania
    Donadio, Michela
    Martinello, Rossella
    Verri, Elena
    Valabrega, Giorgio
    Rocca, Maria Cossu
    Jacomuzzi, Maria Elena
    Viale, Giuseppe
    Sapino, Anna
    Aglietta, Massimo
    [J]. ONCOLOGIST, 2010, 15 (07): : 665 - 672
12345